Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Cancer|August 18, 2017
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myelomaJatin J Shah, Jonathan L Kaufman, Jeffrey A Zonder, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2026
Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient SurveyNadine H Abdallah, Jay R Hydren, Mason S Barnes, et al.
Cancer|July 20, 2016
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myelomaAjai Chari, Myo Htut, Jeffrey A Zonder, et al.
The Lancet. Haematology|December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trialSaad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.
British Journal of Haematology|May 25, 2019
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myelomaAndrzej J Jakubowiak, Jagoda K Jasielec, Cara A Rosenbaum, et al.
Current Medical Research and Opinion|June 25, 2026
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myelomaNaresh Bumma, Hans C Lee, Joshua Richter, et al.
Future Oncology (London, England)|March 1, 2019
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myelomaCaitlin Costello, Faith E Davies, Gordon Cook, et al.
Blood|June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trialMorie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
Leukemia & Lymphoma|July 10, 2026
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparisonJoshua Richter, Hans C Lee, Sundar Jagannath, et al.
Blood Neoplasia|August 7, 2026
Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1James E Hoffman, Naresh Bumma, Joshua Richter, et al.
Pageof 6